News | Stroke | August 24, 2022

iHealthScreen Inc. Introduces An Automated Stroke Prediction Model, based on AI and Color Fundus Imaging

iHealthScreen is the First Company to Develop An AI- and Color-Fundus- Image-Based Stroke Prediction model, Funded by the National Institutes of Health (NIH) 

iHealthScreen is the First Company to Develop An AI- and Color-Fundus- Image-Based Stroke Prediction model, Funded by the National Institutes of Health (NIH) 


August 24, 2022 — iPredict late stroke prediction model provides a fully automated prediction score for incident stroke and identifies the individuals who are at risk of stroke within 5-years. These results were presented at the international conference: Society for Brain Mapping and Therapeutics World Congress and show that the prediction model may help prevent stroke, saving millions of people from death or disability. 

Once high-resolution images of the patient’s eyes have been captured using a color fundus camera and submitted to the iPredict AI System, the stroke prediction results are available in a fully automated report in less than 60 seconds. The entire test can easily and reliably be completed within 5 minutes. 

This prediction model offers an overall accuracy of 82.4% for identifying an individual at risk of having an incident stroke within 5-years. 

iPredict achieved higher accuracy than existing stroke prediction models such as Framingham and Chads scores (iPredict-stroke accuracy 82.4% compared to Framingham score 64.9%, and the CHADS2VASC score achieved 63.8% accuracy respectively on the same dataset). 

iPredict’s stroke model can be used to alert physicians of the need to take further preventive measures for these patients in the primary care setting. 

The company also has AI-based screening tools for early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma which are CE certified and TGA/Australian health approved. 

For more information: https://www.iHealthScreen.org 


Related Content

News | Heart Failure

October 3, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products ...

Home October 03, 2022
Home
News | Heart Failure

September 29, 2022 — Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in ...

Home September 29, 2022
Home
News | Heart Failure

September 28, 2022 — A University of Massachusetts Amherst nurse engineer is leading a team of researchers who are ...

Home September 28, 2022
Home
News | Heart Failure

September 19, 2022 — A first-in-human (FIH) study using the ModulHeart device (Puzzle Medical Devices Inc.) has ...

Home September 19, 2022
Home
News | Heart Failure

September 15, 2022 — Today, aortic stenosis (AS) is one of the most common and serious valve disease problems [1]. It ...

Home September 15, 2022
Home
News | Heart Failure

September 14, 2022 — Minimally invasive, catheter-based transcatheter aortic valve replacement (TAVR) has revolutionized ...

Home September 14, 2022
Home
News | Heart Failure

September 2, 2022 — Dapagliflozin reduces the risk of cardiovascular death or worsening heart failure in heart failure ...

Home September 02, 2022
Home
News | Heart Failure

September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients ...

Home September 02, 2022
Home
News | Heart Failure

September 2, 2022 — Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure ...

Home September 02, 2022
Home
News | Heart Failure

August 29, 2022 — Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) ...

Home August 29, 2022
Home
Subscribe Now